Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Average Rating of “Reduce” by Brokerages

by · The Markets Daily

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) has received a consensus recommendation of “Reduce” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a sell rating and six have given a hold rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $23.5667.

Several brokerages have recently weighed in on FMS. BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective on the stock. in a research report on Tuesday, July 28th. Truist Financial set a $25.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Sanford C. Bernstein increased their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a report on Thursday, August 6th. Finally, Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th.

View Our Latest Stock Report on FMS

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FMS. Morgan Stanley increased its position in Fresenius Medical Care AG & Co. KGaA by 47.2% during the 4th quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock worth $70,027,000 after buying an additional 942,497 shares during the period. Pzena Investment Management LLC boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after acquiring an additional 299,986 shares during the period. Bank of America Corp DE grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after acquiring an additional 248,477 shares in the last quarter. ABC Arbitrage SA grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the fourth quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock valued at $5,950,000 after acquiring an additional 229,589 shares in the last quarter. Finally, Integral Health Asset Management LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 44.4% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after acquiring an additional 200,000 shares during the period. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE FMS opened at $23.71 on Thursday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $12.74 billion, a P/E ratio of 12.28, a P/E/G ratio of 4.43 and a beta of 0.77. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The stock has a 50 day moving average of $23.78 and a 200-day moving average of $23.07.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The business had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. As a group, equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current year.

About Fresenius Medical Care AG & Co. KGaA

(Get Free Report)

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.

See Also